FLT3-ITD mut AML patients treated with LA had a median OS of 437 days (range 5–2379 days) with a corresponding 14-day survival of 92.3%, while FLT3 wt AML patients displayed a significantly lower median OS of only 5 days (range 1–203 days) with a corresponding 14-day survival of 14.3% (log-rank test of OS data; p = 0.0001; see Figure 2). Here, FLT3 is linked to acute myeloid leukemia.